EN
HI
Glenmark Pharmaceuticals Chart
Glenmark Pharmaceuticals Share Key Metrics
Volume
4.55 L
Market Cap
61008.99 CR
LTQ@LTP
6@2161.90
ATP
2171.58
Var Margin
15.53 %
Circuit Range
1983.9-2424.7
Delivery %
41.2 %
Value
98.88 CR
ASM/GSM
No
Market Lot
1
Summary
Glenmark Pharmaceuticals share price is ₹2161.9 as of 2 Jul, 2026. The stock Glenmark Pharmaceuticals intraday movement has stayed between ₹2153.10 and ₹2221.20, while on a 52-week basis,Glenmark Pharmaceuticals price 52 week high is ₹2474.00 & its 52 week low is ₹1680.40.
In terms of trading activity, Glenmark Pharmaceuticals has recorded a volume of 455357 shares, The Glenmark Pharmaceuticals has a market cap of ₹282200809 CR. The stock’s Average Traded Price (ATP) stands at ₹2171.58, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 6 @ ₹2161.90.
Glenmark Pharmaceuticals operates within a circuit range of ₹1983.90 – ₹2424.70, with a Value of ₹98.88 CR. The Delivery Percentage for the day is 41.2%. Additionally, Glenmark Pharmaceuticals currently falls under the No framework, and trades with a market lot size of 1.
Glenmark Pharmaceuticals Fundamentals
P/E Ratio
45.69
P/B Ratio
5.92
Div. Yield
0.11
Sector P/E
70.76
Sector P/B
3.21
Sec. Div. Yield
0.53
Glenmark Pharmaceuticals Resistance and Support
Pivot 2202.93
Resistance
First Resistance
2221.36
Second Resistance
2238.43
Third Resistance
2256.86
Support
First Support
2185.86
Second Support
2167.43
Third Support
2150.36
Glenmark Pharmaceuticals Futures & Options
Glenmark Pharmaceuticals Option Chain
View Price, OI, Greeks & More...
28JUL26
2167.00
-52.20 (2.35%)
25AUG26
2182.00
-49.60 (2.22%)
29SEP26
2200.00
2200.00 (Infinity%)
GLENMARK|28JUL26 CE 2160.00
70.35
-36.5 (-34.16%)
GLENMARK|28JUL26 PE 2180.00
69.2
20.35 (41.66%)
Glenmark Pharmaceuticals Corporate Actions
| Date | Agenda |
|---|---|
| 2026-05-29 | Audited Results & Final Dividend |
| 2026-01-30 | Quarterly Results |
| 2025-11-14 | Quarterly Results |
| 2025-09-26 | Interim Dividend |
| 2025-08-14 | Quarterly Results |
| 2025-05-23 | Audited Results & Final Dividend |
| 2025-02-14 | Quarterly Results |
Glenmark Pharmaceuticals News
Glenmark Pharmaceuticals Ltd - 532296 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Glenmark Pharmaceuticals' manufacturing facility in Goa received a Form 483 with six procedural observations from the US FDA after a recent inspection. The company stated that these observations are not related to data integrity, are not repeat observations, and anticipates no impact on commercial product supply.
Jun 30 2026 22:01:19
Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals Inc., USA has launched Methylene Blue Injection USP, 50 mg/10 mL Single-Dose Vial in the US. This new product is therapeutically equivalent to the reference drug ProvayBlue®, which has an annual market value of approximately $19.0 million. The launch strengthens Glenmark's institutional portfolio in the U.S.
Jun 17 2026 08:38:12
Read More
Glenmark Pharmaceuticals Management
| Name | Position |
|---|---|
| Rashmi Khandelwal | Company Secretary & Compliance Officer |
| Glenn Saldanha | Chairman & Managing Director |
Glenmark Pharmaceuticals Similar Stocks
Lenskart Solutions Ltd.
530.55
15.60 (3.03%)
Laurus Labs Ltd.
1493.30
-24.10 (1.59%)
Fortis Healthcare Ltd.
949.05
-7.90 (0.83%)
Biocon Ltd.
418.20
-0.10 (0.02%)
Alkem Laboratories Ltd.
5567.50
-2.50 (0.04%)
Abbott India Ltd.
25550.00
110.00 (0.43%)
Anthem Biosciences Ltd.
763.10
-7.45 (0.97%)
Ajanta Pharma Ltd.
3347.50
-75.20 (2.20%)
Ipca Laboratories Ltd.
1696.40
-4.60 (0.27%)
Glenmark Pharmaceuticals FAQs
The Buying Price of Glenmark Pharmaceuticals share is 2161.9 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.
To buy Glenmark Pharmaceuticals stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Glenmark Pharmaceuticals, choose your preferred order type, and place the trade.
The Price-to-earnings (P/E) ratio of Glenmark Pharmaceuticals shares is 45.69. You can compare it with the sector average for relative valuation.
The Price to Book (P/B) ratio Glenmark Pharmaceuticals shares is 5.92. Useful to assess the stock's value relative to its book value.
To assess Glenmark Pharmaceuticals’s valuation compare Sector P/E, P/B which are 70.76 & 3.21 with sector averages, along with growth rates and financial metrics.
The Market Cap of Glenmark Pharmaceuticals is 61008.99 CR. It indicates the company's size category and trading liquidity.
The 52 week high and low prices of Glenmark Pharmaceuticals share price is 2474.00 & 1680.40. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.
Glenmark Pharmaceuticals belongs to the Healthcare sector.
Made for Traders.
Trusted by Investors.
Download FinX — trade confidently, invest
smarter, track everything.
